MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, is moving toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector.
The company recently appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from development to market entry. MindBio’s technology analyzes voice patterns to detect intoxication or impairment without biological testing, and management is positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries.
Chile’s mining sector, employing more than 200,000 workers, represents an early target market. The company is preparing to deploy its voice-based AI drug and alcohol impairment detection platform in industrial environments beginning in 2026. The appointment of Leyton, who has deep expertise in Chilean drug policy and regulatory frameworks, is expected to facilitate partnerships with mining companies and government agencies.
MindBio also recently closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities. The funding will be used to advance the platform’s integration into workplace safety protocols and to expand the company’s presence in South America.
The voice-based impairment detection technology offers a non-invasive alternative to traditional biological testing methods such as blood, urine, or saliva tests. By analyzing vocal biomarkers, the AI can identify signs of impairment in real time, enabling employers to quickly assess workers’ fitness for duty without requiring laboratory analysis or sample collection.
“This is a significant step forward for workplace safety,” said a company spokesperson. “Our technology can help prevent accidents caused by impairment, especially in high-risk industries like mining where even a momentary lapse can have catastrophic consequences.”
The platform has undergone extensive testing and validation, and MindBio is now focusing on regulatory approvals and pilot programs with potential customers. The company’s strategy aligns with growing global emphasis on occupational health and safety, particularly in industries with high injury rates.
For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
